Journal of Clinical Oncology
Articles in this Issue
Real-world analysis of adverse events associated with KIMMTRAK in metastatic uveal melanoma using the FAERS database.
e21511 Background: KIMMTRAK (tebentafusp-tebn) is a bispecific T-cell engager approved for the treatment of metastatic uveal melanoma, a rare but aggressi...
The expression of human endogenous retrovirus env-gene product as a hallmark of sidedness in operable colorectal cancer.
e15632 Background: Human Endogenous Retroviruses (HERV) constitute 8% of the human genome, where they are integrated, and usually not expressed. Despite t...
Trends in utilization of active surveillance, treatment, and survival in prostate cancer: Insights from the National Cancer Database (NCDB) analysis.
e17138 Background: Active surveillance (AS) is one of the standard approach recommended for most prostate cancer men with low-risk prostate cancer. We exa...
Results from a phase I study of KL590586 in patients with advanced RET-mutant medullary thyroid cancer.
6098 Background: RET mutations occur in 70% of medullary thyroid cancers (MTC). KL590586 (A400/EP0031) is a potent next-generation brain-penet...
Using single-cell sequencing to identify endothelial expression of immune checkpoint ligands in advanced hepatocellular carcinoma, pre- and post- atezolizumab plus bevacizumab in the phase II INTEGRATE study.
3129 Background: Atezolizumab (atezo; anti-PD-L1) plus bevacizumab (bev; anti-VEGF-A) became a standard treatment for advanced hepatocellular carcinoma (H...
Evaluation of current programmed death-ligand 1 (PD-L1) testing practices for metastatic non-small cell lung cancer (mNSCLC): Insights from a large network of US community oncology practices.
e23294 Background: PD-L1 testing has become crucial for guiding immunotherapy in mNSCLC and evidence suggests increasing adoption of PD-L1 testing in the...
Genomic instability score (GIS) and benefit from olaparib (ola) and bevacizumab (bev) maintenance in high-grade ovarian cancer (HGOC): Phase III PAOLA-1 GINECO/ENGOT-ov25 trial exploratory analysis.
5576 Background: The PAOLA-1 trial showed that adding ola to bev as maintenance therapy improved overall survival (OS) of HGOC patients with B...
Trends in preferred place of death for metastatic melanoma patients in the United States from 2015 to 2024: Analysis of CDC WONDER database.
e21523 Background: Metastatic melanoma (MM) is a leading cause of skin cancer-related mortality, necessitating a better understanding of end-of-life care...
Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [ <sup>177</sup> Lu] Lu-PSMA-617 (ANZUP1901).
5011 Background: [ 68 Ga]Ga-PSMA-11 PET (PSMA-PET) standardized uptake value (SUV)mean and total tumor volume (PSMA-TTV) have been...
Early detection and neoadjuvant efficacy prediction for esophageal cancer using cfDNA methylation-based liquid-biopsy assay.
4070 Background: Esophageal cancer (EC) is a major malignancy of the upper gastrointestinal tract globally. Early detection and timely therapeutic interve...
Efficacy and safety in advanced intrahepatic cholangiocarcinoma using pembrolizumab combined with lenvatinib and GEMOX: A retrospective analysis of real-world evidence.
e16191 Background: The TOPAZ-1 and KEYNOTE-966 trials have established GemCis and PD1/PDL1 inhibitors as the standard first-line treatments for advanced b...
Ultrasensitive ctDNA monitoring to reveal early predictors of immunotherapy success in advanced cancer.
2561 Background: The potential of immune checkpoint inhibition (ICI) therapy is constrained by the inability to predict patient response. Circulating tumo...
Efficacy and safety of surufatinib (Sur) plus paclitaxel (Pac) as second line (2L) treatment for advanced gastric cancer (aGC): Final results from a phase 2 trial.
4028 Background: Standard chemotherapy (ChT) provides unsatisfactory efficacy for patients with aGC in the 2L setting. Recent studies have suggested impro...
Comparative safety and efficacy of tislelizumab with or without chemotherapy versus chemotherapy alone in patients with lung cancer: A systematic review and meta-analysis.
e20593 Background: Tislelizumab, an anti-PD-1 antibody, is emerging as a promising immunotherapy agent and has demonstrated clinical benefit and acceptabl...
Dyslipidemia in long-term survivors of testicular germ cell tumors.
e17017 Background: Dyslipidemia is a significant modifiable risk factor for cardiovascular diseases (CVD). An increased risk of CVD in survivors of testic...
Real-world treatment patterns and outcomes of triple class exposed (TCE) patients with relapsed/refractory multiple myeloma (RRMM) treated in community and academic oncology practices in the US.
e23261 Background: Treatment accessibility for patients (pts) with MM is variable based on care setting. Most novel therapies are approved for RRMM in lat...
Targeting preventable acute care events: A study on which patients experience emergency visits and hospitalizations during outpatient systemic therapy for cancer care.
e13585 Background: Preventable acute care events within 30 days of systemic therapy administration (PACE30) represent significant clinical and economic bu...
Neuroendocrine marker expression in dendritic cell sarcoma.
e23557 Background: Dendritic cell sarcoma (DCS) is a rare type of cancer that can involve lymph nodes (“follicular”) or occur outside of lymph nodes (“int...
Neoadjuvant chemoradiotherapy combined with tislelizumab for locally advanced rectal cancer: A phase II clinical trial.
e15624 Background: Surgical resection remains the cornerstone treatment for locally advanced rectal cancer. However, for patients at high risk of recurren...
OnPOINT: Development of an open navigator through precision oncology informatics technology to support precision oncology decisions and genotype-matched clinical trial enrollment.
e13672 Background: The growing compendium of genomic alterations linked to FDA-approved therapies or drugs in development, requires the implementation of...
Colorectal cancer screening and detection following USPSTF recommendations for ages 45-49: Insights from a large EHR cohort.
3623 Background: Rising colorectal cancer (CRC) incidence in relatively younger adults prompted the US Preventative Services Task Force (USPSTF) to recomm...
Evaluation of plasma methylated DNA markers for detection HPV-positive oropharyngeal squamous cell carcinoma: A case control study.
6057 Background: The incidence rate of human papillomavirus associated oropharyngeal squamous cell carcinoma (HPV(+)OPSCC) has persistently increased over...
Ipilimumab and nivolumab in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated on the phase 3 PDIGREE (Alliance A031704) trial: Results from Step 1 analysis.
4516 Background: Ipilimumab/nivolumab (ipi/nivo) is a standard of care first-line treatment (tx) for patients (pts) with mccRCC; however, ideal timing of...
Prophylactic acetaminophen regimen to prevent cytokine release syndrome with teclistamab or talquetamab: A single-center experience.
e19509 Background: Teclistamab-cqyv and talquetamab-tgvs are bispecific T-cell engagers approved for relapsed/refractory multiple myeloma (MM) after at le...
Mainstreaming the diagnosis of Lynch syndrome (LS) in colorectal cancer (CRC) patients: The ItaLynch study.
10580 Background: International guidelines recommend universal screening for LS through somatic DNA mismatch repair deficiency (dMMR) testing in CRC. Howe...